Caris Life Sciences, Inc.CAIEarnings & Financial Report
Nasdaq
NextMar 31, 2026
CAI Q3 2025 Key Financial Metrics
营收
$216.8M
毛利润
N/A
营业利润
$32.6M
净利润
$24.3M
毛利率
N/A
营业利润率
15.1%
净利率
11.2%
同比增长
113.4%
EPS
$0.08
资金流向
Caris Life Sciences, Inc. Q3 2025 Financial Summary
Caris Life Sciences, Inc. reported revenue of $216.8M for Q3 2025, with a net profit of $24.3M (11.2% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $216.8M |
|---|---|
| Net Profit | $24.3M |
| Gross Margin | N/A |
| Operating Margin | 15.1% |
| Report Period | Q3 2025 |
利润表
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| 营收 | $100.0M | $101.6M | $181.4M | $216.8M |
| 同比增长 | N/A | N/A | 81.3% | 113.4% |
资产负债表
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| 总资产 | N/A | N/A | $955.1M | $984.6M |
| 总负债 | N/A | N/A | $502.2M | $506.2M |
| 股东权益 | $-2.36B | $-2.44B | $452.9M | $478.4M |
现金流量表
| Q3 2025 | |
|---|---|
| 经营性现金流 | $62.4M |